SCHEMBL6249003

SCHEMBL6249003

CSc1ccc(C(F)(F)F)cn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.49
RAB9A P51151 3/20 0.49
NPSR1 Q6W5P4 1/20 0.49
ALDH1A1 P00352 5/20 0.47
RECQL P46063 1/20 0.47
PKM P14618 1/20 0.46
DDB1 Q16531 1/20 0.43
CRBN Q96SW2 1/20 0.43
KMT2A Q03164 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.42
DYRK3 O43781 1/20 0.41
CCNT1 O60563 1/20 0.41
CCNA2 P20248 1/20 0.41
CDK2 P24941 1/20 0.41
CDK9 P50750 1/20 0.41
CDK5 Q00535 1/20 0.41
DYRK1A Q13627 1/20 0.41
CDK5R1 Q15078 1/20 0.41
DYRK2 Q92630 1/20 0.41
DYRK1B Q9Y463 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13768076 0.86 RAB9A (0.37) KDM4ERAB9ANPSR1ALDH1A1RECQL
SCHEMBL25325181 0.83 RAB9A (0.51) KDM4ERAB9ANPSR1ALDH1A1RECQL
SCHEMBL2616412 0.81 RAB9A (0.36) KDM4ERAB9ANPSR1ALDH1A1RECQL
SCHEMBL3323097 0.79 RAB9A (0.49) KDM4ERAB9ANPSR1ALDH1A1RECQL
SCHEMBL28737917 0.79 RAB9A (0.49) KDM4ERAB9ANPSR1ALDH1A1RECQL
SCHEMBL14350432 0.79 ALDH1A1 (0.52) KDM4ERAB9ANPSR1ALDH1A1RECQL
SCHEMBL22928065 0.79 RAB9A (0.45) KDM4ERAB9ANPSR1ALDH1A1RECQL
SCHEMBL20381801 0.76 ALDH1A1 (0.57) KDM4ERAB9ANPSR1ALDH1A1RECQL
SCHEMBL16068106 0.75 FEN1 (0.43) ALDH1A1RECQLDYRK3CCNT1CCNA2
SCHEMBL23048491 0.75 ALDH1A1 (0.47) KDM4ERAB9ANPSR1ALDH1A1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023147418-A1 PARP7 INHIBITORS GILEAD SCIENCES, INC. (US) 2023-08-03 WO disclosed
US-20230242514-A1 BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS CORCEPT THERAPEUTICS INCORPORATED 2023-08-03 US disclosed
US-20220127239-A1 GLYCOSYL DONOR, PREPARATION METHOD THEREFOR, AND USE THEREOF SICHUAN UNIVERSITY (CN) 2022-04-28 US disclosed
WO-2021013155-A1 NOVEL GLYCOSYL DONOR, PREPARATION METHOD THEREFOR, AND USE THEREOF 四川大学 2021-01-28 WO disclosed
EP-2978764-B1 PYRAZOLONAPHTHYRIDINONE DERIVATIVES AS METAP2 INHIBITORS (METHIONINE AMINOPEPTIDASE TYPE-2) SANOFI SA (FR) 2017-04-19 EP disclosed
CN-106458956-A Heteroaryl substituted heterocyclyl sulfones 格吕伦塔尔有限公司 2017-02-22 CN disclosed
US-7666869-B2 to provide an aliphatic nitrogen-containing 5-membered ring compound represented by the formula [I]:** Image-1wherein symbols in the formula have the following meanings;A: CH2 or S , antidiabetic agents MITSUBISHI TANABE PHARMA CORP. (JP) 2010-02-23 US disclosed
US-7666869-B2 to provide an aliphatic nitrogen-containing 5-membered ring compound represented by the formula [I]:** Image-1wherein symbols in the formula have the following meanings;A: CH2 or S , antidiabetic agents MITSUBISHI TANABE PHARMA CORP. (JP) 2010-02-23 US disclosed
US-20080153821-A1 Nitrogen-containing 5-membered ring compound TANABE SEIYAKU CO., LTD. 2008-06-26 US disclosed
US-20080153821-A1 Nitrogen-containing 5-membered ring compound TANABE SEIYAKU CO., LTD. 2008-06-26 US disclosed
US-7332487-B2 Nitrogen-containing 5-membered ring compound TANABE SEIYAKU CO., LTD. (JP) 2008-02-19 US disclosed
US-7332487-B2 Nitrogen-containing 5-membered ring compound TANABE SEIYAKU CO., LTD. (JP) 2008-02-19 US disclosed
WO-2005044008-A2 2 -AMINOTHIOPHENE COMPOUNDS AS FUNGICIDES SYNGENTA PARTICIPATIONS AG (CH) 2005-05-19 WO disclosed
EP-1329160-A2 4-ACYLAMINOPYRAZOLE DERIVATIVES Sankyo Company, Limited (JP) 2003-07-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220127239-A1 GLYCOSYL DONOR, PREPARATION METHOD THEREFOR, AND USE THEREOF UGGT1, ALG8, FUT6 KDM4E 3473/4885RAB9A 1546/4885NPSR1 3338/4885
US-20230242514-A1 BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS NR3C1, NR3C2, NR1I2 KDM4E 4539/4885RAB9A 4839/4885NPSR1 883/4885
US-20080153821-A1 Nitrogen-containing 5-membered ring compound ALK, SCO2, NPR1 KDM4E 2117/4885RAB9A 4247/4885NPSR1 894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.